Is It Cost Effective to Obtain Fungal and Acid-Fast Bacillus Cultures during Spine Debridement?

• Published in: Asian spine journal Vol. 16; no. 4; pp. 519 - 525
• Main Authors: Lambrechts, Mark J, Clair, Devin D St, Li, Jinpu, Cook, James L, Spence, Bradley S, Leary, Emily V, Choma, Theodore J, Moore, Donald K, Goldstein, Christina L
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Society of Spine Surgery 01.08.2022; Korean Spine Society; 대한척추외과학회
• Subjects: Age; antifungal agents; bacillus; Back surgery; Bacterial infections; Chronic obstructive pulmonary disease; Clinical Study; Comorbidity; Cost analysis; Cost control; cost-benefit analysis; cost-savings; Debridement; Diabetes; Fungal infections; fungi; Health care policy; Hospital costs; lumbar spine; Medicare; Morbidity; Patients; Reimbursement; Risk factors; Steroid hormones; surgical wound infection; 정형외과학; United States > US; Missouri; Cost-benefit analysis; Fungi; Lumbar spine; Cost-savings; Antifungal agents; Bacillus; Surgical wound infection
• ISSN: 1976-1902; 1976-7846
• DOI: 10.31616/asj.2021.0169

Retrospective study. To identify the rate of positive acid-fast bacillus (AFB) and fungal cultures during spine debridement, determine whether these infections are more common in certain spine segments, identify comorbidities associated with these infections, and determine whether the universal performance of fungal and AFB cultures during spine debridement is cost effective. Spine infections are associated with significant morbidity and costs. Spine fungal and AFB infections are rare, but their incidence has not been well documented. As such, guidance regarding sample procurement for AFB and fungal cultures is lacking. A retrospective review of medical record data from patients undergoing spine irrigation and debridement (I&D) at the University of Missouri over a 10-year period was performed. For patients undergoing spine I&D, there was a 4% incidence of fungal infection and 0.49% rate of AFB infection. Steroid use was associated with a higher likelihood (odds ratio, 5.62; 95% confidence interval, 1.33-23.75) of positive fungal or AFB cultures. Although not significant, patients undergoing multiple I&D procedures had higher rates of positive fungal cultures during each subsequent I&D. Over a 10-year period, if fungal cultures are obtained for each patient, it would cost our healthcare system $12,151.58. This is compared to an average cost of $177,297.64 per missed fungal infection requiring subsequent treatment. Spine fungal infections occur infrequently at a rate of 4%. Physicians should strongly consider obtaining samples for fungal cultures in patients undergoing spine I&D, especially those using steroids and those undergoing multiple I&Ds. Our AFB culture rates mirror the false positive rates seen in previous orthopedic literature. It is unlikely to be cost effective to send for AFB cultures in areas with low endemic rates of AFB.